EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the Company’s License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company’s EyeGate(R) II Delivery System and EGP-437 combination product (the “Product”) in post-operative ocular inflammation and pain in ocular surgery patients.
We are going to take a close look at Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today’s focus will be a fundamental evaluation of the stock from top to bottom.
As such, let’s start with the top line: Revenue trends.
Last quarter, the company saw its overall sales move to $184,532 in total revenues. That represents an overall change in revenues, on a quarterly year/year basis, of 1%. If we translate that into sequential terms, the company saw sales grow by 0.13% from quarter to quarter.
It?s important to closely track the top line data. There’s no better way to measure the end market’s reception of a company?s products. But no one truly wins without bottom line success, which is what we need to look at next.
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 10.46M, this means an overall earnings per share of $(0.28). Note, this compares with a consensus analyst forecast of $-0.28 in earnings per share for its next fiscal quarterly report.
Given that data, we now turn to a more thorough glance across analyst expectations for the company going forward.
At present, analysts hold a consensus average recommendation of Buy. This is based on a total of 1. While we don’t suggest taking analyst recommendations as face value plans for action in a portfolio, we do think it is important to note where consensus is on a stock to understand what basic assumptions are perhaps already discounted into market pricing of shares of the stock.
As far as price targets, analysts currently have an average target on shares of at $6.00. In addition, if we turn to next year, we see estimates of a fiscal year forecast to bring about -0.95 in total earnings per share. On a median price to earnings ratio basis, that outlook adds up to a valuation of $N/A times earnings.
At this point, we?ve taken a thorough look at this company from top to bottom, and gotten a sense of what analysts are expecting. But underneath it all, when push comes to shove, companies make it through tough times on balance sheet strength. With that in mind, we should take a look under the hood here.
As the reader is no doubt aware, for any company, balance sheet health sits at the heart of the company’s capacity to stand up to the demands and obligations incurred by normal and contingent operations, which in turn lies at the core of a company’s ability to retain the faith of investors in the marketplace. For Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG), the company presently holds about $5.44M in cash in the coffers. That cash is balanced against about $12,645 in total current liabilities.
It’s important to consider both a static and dynamic picture, particularly where debt levels are concerned. This means, we need to take into account any trends. In this case, the company?s debt has been $growing. The company also has $12.06M in total assets, balanced by $13.15M in total liabilities, which suggests where this story might go under adverse economic or financial conditions.
As far as cash flows, the company saw a free cash flow last quarter of $(18,601), representing a quarterly net change in cash of $1.8M. On a net operating level, the company saw about $(18,601) in cash flow.
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
We will update the interesting story of Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) as new events transpire.